Grants and Contributions:
Title:
ARP - MNC Collab - Immuno-Nuc-Nab - Development and Validation of CRISPR RNP delivery to Immune Cell populations
Agreement Number:
1023213
Agreement Value:
$75,000.00
Agreement Date:
Oct 1, 2024 - Mar 28, 2025
Description:
The project will focus on developing a suite of gene editing complexes capable of delivering gene edits in vivo to specific cell types. The goal is to modify, correct, or enhance cell behaviors, enabling a wide range of new therapeutic developments in key areas. This will expand treatment options and accelerate the company's growth.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Cote-Saint-Luc, Quebec, CA H4W 1K7
Reference Number:
172-2024-2025-Q3-1023213
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
701783482
Recipient Type:
For-profit organization
Recipient's Operating Name:
Jenthera Therapeutics Inc.
Recipient's Legal Name:
Jenthera Therapeutics Inc.
Federal Riding Name:
Mount Royal
Federal Riding Number:
24052
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
339110